$2.68T
Total marketcap
$57.31B
Total volume
BTC 49.89%     ETH 17.08%
Dominance

Amphastar Pharmaceuticals, Inc. 29A.F Stock

38.05 EUR {{ price }} -3.328256% {{change_pct}}%
COUNTRY
Germany
Exchange
Frankfurt
Market Cap
1.86B EUR
LOW - HIGH [24H]
38.05 - 38.05 EUR
VOLUME [24H]
12 EUR
{{ volume }}
P/E Ratio
14.19
Earnings per share
2.68 EUR

Amphastar Pharmaceuticals, Inc. Price Chart

Amphastar Pharmaceuticals, Inc. 29A.F Financial and Trading Overview

Amphastar Pharmaceuticals, Inc. stock price 38.05 EUR
Previous Close 43.4 EUR
Open 47 EUR
Bid 47 EUR x 70000
Ask 48.6 EUR x 70000
Day's Range 47 - 47 EUR
52 Week Range 25.8 - 47 EUR
Volume 23 EUR
Avg. Volume 2 EUR
Market Cap 2.38B EUR
Beta (5Y Monthly) 0.76514
PE Ratio (TTM) 28.658537
EPS (TTM) 2.68 EUR
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 22.75 EUR

29A.F Valuation Measures

Enterprise Value 2B EUR
Trailing P/E 28.658537
Forward P/E 33.57143
PEG Ratio (5 yr expected) 0.77
Price/Sales (ttm) 4.580199
Price/Book (mrq) 4.1278763
Enterprise Value/Revenue 3.864
Enterprise Value/EBITDA 13.815

Trading Information

Amphastar Pharmaceuticals, Inc. Stock Price History

Beta (5Y Monthly) 0.76514
52-Week Change 48.63%
S&P500 52-Week Change 20.43%
52 Week High 47 EUR
52 Week Low 25.8 EUR
50-Day Moving Average 37.44 EUR
200-Day Moving Average 30.97 EUR

29A.F Share Statistics

Avg. Volume (3 month) 2 EUR
Avg. Daily Volume (10-Days) 2 EUR
Shares Outstanding 48.27M
Float 37.67M
Short Ratio N/A
% Held by Insiders 22.04%
% Held by Institutions 62.57%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 17.96%
Operating Margin (ttm) 23.00%
Gross Margin 51.45%
EBITDA Margin 27.97%

Management Effectiveness

Return on Assets (ttm) 10.00%
Return on Equity (ttm) 18.12%

Income Statement

Revenue (ttm) 518.64M EUR
Revenue Per Share (ttm) 10.69 EUR
Quarterly Revenue Growth (yoy) 16.30%
Gross Profit (ttm) 248.86M EUR
EBITDA 145.08M EUR
Net Income Avi to Common (ttm) 93.17M EUR
Diluted EPS (ttm) 1.64
Quarterly Earnings Growth (yoy) 7.29%

Balance Sheet

Total Cash (mrq) 192.89M EUR
Total Cash Per Share (mrq) 4 EUR
Total Debt (mrq) 102.03M EUR
Total Debt/Equity (mrq) 18.6 EUR
Current Ratio (mrq) 3.859
Book Value Per Share (mrq) 11.386

Cash Flow Statement

Operating Cash Flow (ttm) 78.8M EUR
Levered Free Cash Flow (ttm) 48.49M EUR

Profile of Amphastar Pharmaceuticals, Inc.

Country Germany
State CA
City Rancho Cucamonga
Address 11570 6th Street
ZIP 91730
Phone 909 980 9484
Website https://www.amphastar.com
Industry Drug Manufacturers-Specialty & Generic
Sector(s) Healthcare
Full Time Employees 1615

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Q&A For Amphastar Pharmaceuticals, Inc. Stock

What is a current 29A.F stock price?

Amphastar Pharmaceuticals, Inc. 29A.F stock price today per share is 38.05 EUR.

How to purchase Amphastar Pharmaceuticals, Inc. stock?

You can buy 29A.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Amphastar Pharmaceuticals, Inc.?

The stock symbol or ticker of Amphastar Pharmaceuticals, Inc. is 29A.F.

Which industry does the Amphastar Pharmaceuticals, Inc. company belong to?

The Amphastar Pharmaceuticals, Inc. industry is Drug Manufacturers-Specialty & Generic.

How many shares does Amphastar Pharmaceuticals, Inc. have in circulation?

The max supply of Amphastar Pharmaceuticals, Inc. shares is 48.9M.

What is Amphastar Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?

Amphastar Pharmaceuticals, Inc. PE Ratio is 14.19776100 now.

What was Amphastar Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?

Amphastar Pharmaceuticals, Inc. EPS is 2.68 EUR over the trailing 12 months.

Which sector does the Amphastar Pharmaceuticals, Inc. company belong to?

The Amphastar Pharmaceuticals, Inc. sector is Healthcare.